Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AVITA Medical (RCEL) EBIT (2018 - 2025)

AVITA Medical's EBIT history spans 8 years, with the latest figure at $21.9 million for Q4 2025.

  • For Q4 2025, EBIT fell 34.86% year-over-year to $21.9 million; the TTM value through Dec 2025 reached -$10.2 million, up 21.37%, while the annual FY2025 figure was -$10.2 million, 21.39% up from the prior year.
  • EBIT reached $21.9 million in Q4 2025 per RCEL's latest filing, up from -$9.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $33.7 million in Q4 2024 to a low of -$17.2 million in Q1 2024.
  • Average EBIT over 5 years is -$3.9 million, with a median of -$9.2 million recorded in 2025.
  • The largest YoY upside for EBIT was 488.73% in 2023 against a maximum downside of 75.5% in 2023.
  • A 5-year view of EBIT shows it stood at -$5.9 million in 2021, then increased by 0.69% to -$5.9 million in 2022, then skyrocketed by 488.73% to $23.0 million in 2023, then soared by 46.56% to $33.7 million in 2024, then plummeted by 34.86% to $21.9 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's EBIT are $21.9 million (Q4 2025), -$9.2 million (Q3 2025), and -$11.1 million (Q2 2025).